BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 29509845)

  • 1. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
    Varughese T; Taur Y; Cohen N; Palomba ML; Seo SK; Hohl TM; Redelman-Sidi G
    Clin Infect Dis; 2018 Aug; 67(5):687-692. PubMed ID: 29509845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
    Ruchlemer R; Ben-Ami R; Bar-Meir M; Brown JR; Malphettes M; Mous R; Tonino SH; Soussain C; Barzic N; Messina JA; Jain P; Cohen R; Hill B; Mulligan SP; Nijland M; Herishanu Y; Benjamini O; Tadmor T; Okamoto K; Arthurs B; Gottesman B; Kater AP; Talha M; Eichhorst B; Korem M; Bogot N; De Boer F; Rowe JM; Lachish T
    Mycoses; 2019 Dec; 62(12):1140-1147. PubMed ID: 31520441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Titus-Rains KS; Brown JN; Hammond JM
    J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
    Lee CS; Rattu MA; Kim SS
    J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
    Kreiniz N; Bejar J; Polliack A; Tadmor T
    Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report.
    Grossi O; Pineau S; Sadot-Lebouvier S; Hay B; Delaunay J; Miailhe AF; Bretonnière C; Jeddi F; Lavergne RA; Le Pape P
    Clin Microbiol Infect; 2019 Feb; 25(2):261-263. PubMed ID: 30691617
    [No Abstract]   [Full Text] [Related]  

  • 10. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib: first global approval.
    Cameron F; Sanford M
    Drugs; 2014 Feb; 74(2):263-71. PubMed ID: 24464309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR
    Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
    Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
    JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
    Shaikh H; Khattab A; Faisal MS; Chilkulwar A; Albrethsen M; Sadashiv S; Fazal S
    J Oncol Pharm Pract; 2019 Jul; 25(5):1265-1270. PubMed ID: 30045682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy.
    Mascarella MA; Schweitzer L; Alreefi M; Silver J; Caglar D; Loo VG; Richardson K; Dufresne P; Lee TC; Sadeghi N
    J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):49. PubMed ID: 31619294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
    de Claro RA; McGinn KM; Verdun N; Lee SL; Chiu HJ; Saber H; Brower ME; Chang CJ; Pfuma E; Habtemariam B; Bullock J; Wang Y; Nie L; Chen XH; Lu DR; Al-Hakim A; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Aug; 21(16):3586-90. PubMed ID: 26275952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.